DK2932980T3 - Multivalent pneumokok-polysaccharid-proteinkonjugatsammensætning - Google Patents
Multivalent pneumokok-polysaccharid-proteinkonjugatsammensætning Download PDFInfo
- Publication number
- DK2932980T3 DK2932980T3 DK13862871.4T DK13862871T DK2932980T3 DK 2932980 T3 DK2932980 T3 DK 2932980T3 DK 13862871 T DK13862871 T DK 13862871T DK 2932980 T3 DK2932980 T3 DK 2932980T3
- Authority
- DK
- Denmark
- Prior art keywords
- pneumokok
- polysaccharid
- multivalent
- protein conjugate
- conjugate composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120143318A KR20140075201A (ko) | 2012-12-11 | 2012-12-11 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| PCT/KR2013/011195 WO2014092378A1 (ko) | 2012-12-11 | 2013-12-05 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2932980T3 true DK2932980T3 (da) | 2021-07-19 |
Family
ID=50934609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13862871.4T DK2932980T3 (da) | 2012-12-11 | 2013-12-05 | Multivalent pneumokok-polysaccharid-proteinkonjugatsammensætning |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150343076A1 (da) |
| EP (1) | EP2932980B1 (da) |
| JP (1) | JP2016503016A (da) |
| KR (1) | KR20140075201A (da) |
| CN (1) | CN104837504A (da) |
| BR (1) | BR112015013513B1 (da) |
| CA (1) | CA2894532C (da) |
| CO (1) | CO7461130A2 (da) |
| DK (1) | DK2932980T3 (da) |
| ES (1) | ES2881541T3 (da) |
| MX (1) | MX366762B (da) |
| PH (1) | PH12015501270A1 (da) |
| PL (1) | PL2932980T3 (da) |
| PT (1) | PT2932980T (da) |
| RU (1) | RU2613148C2 (da) |
| WO (1) | WO2014092378A1 (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2425853A1 (en) | 2005-04-08 | 2012-03-07 | Wyeth LLC | Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| PT3096783T (pt) * | 2014-01-21 | 2021-08-16 | Pfizer | Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos |
| WO2016178123A1 (en) | 2015-05-04 | 2016-11-10 | Pfizer Inc. | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| HUE053272T2 (hu) * | 2015-06-23 | 2021-06-28 | Biological E Ltd | Multivalens konjugált pneumococcus vakcina |
| TWI720448B (zh) | 2015-07-21 | 2021-03-01 | 美商輝瑞股份有限公司 | 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途 |
| KR20210011083A (ko) * | 2015-09-10 | 2021-01-29 | 인벤트프라이즈 엘엘씨 | 다가 vlp 접합체 |
| US20180271969A1 (en) * | 2015-10-07 | 2018-09-27 | Boehringer Ingelheim Vetmedica, Inc. | Streptococcus suis polysaccharide-protein conjugate composition |
| KR102608081B1 (ko) * | 2016-09-30 | 2023-11-29 | 바이오로지칼 이 리미티드 | 폴리사카라이드-단백질 접합체를 포함하는 다가 폐렴구균 백신 조성물 |
| CN110366428B (zh) | 2016-12-30 | 2024-05-17 | Vaxcyte公司 | 具有非天然氨基酸的多肽-抗原缀合物 |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| US11090374B2 (en) * | 2017-02-24 | 2021-08-17 | Merck Sharp & Dohme Corp. | Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates |
| JP7218358B2 (ja) | 2017-09-07 | 2023-02-06 | メルク・シャープ・アンド・ドーム・エルエルシー | 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用 |
| BR112020004471A8 (pt) | 2017-09-07 | 2022-11-01 | Merck Sharp & Dohme | Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora |
| CA3084436A1 (en) | 2017-12-06 | 2019-07-18 | Merck Sharp & Dohme Corp. | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| CN108159408A (zh) * | 2017-12-29 | 2018-06-15 | 云南沃森生物技术股份有限公司 | 一种多价肺炎球菌多糖-蛋白结合物组合物及其制备方法和应用 |
| KR102486891B1 (ko) | 2018-02-05 | 2023-01-10 | 사노피 파스퇴르 인코포레이티드 | 다가 폐렴구균성 다당류-단백질 접합체 조성물 |
| CA3096358A1 (en) * | 2018-04-18 | 2019-10-24 | Sk Bioscience Co., Ltd. | Streptococcus pneumoniae capsular polysaccharide and immunogenic conjugate thereof |
| EP3897705A2 (en) | 2018-12-19 | 2021-10-27 | Merck Sharp & Dohme Corp. | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| WO2023039223A1 (en) | 2021-09-09 | 2023-03-16 | Affinivax, Inc. | Multivalent pneumococcal vaccines |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4902506A (en) | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| CA2059693C (en) | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Polysaccharide antigens from streptococcus pneumoniae |
| IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
| JPH07507854A (ja) | 1991-12-23 | 1995-08-31 | ツォッヒェ，ミヒャエル | 油除去装置を備えたエンジン |
| ATE280235T1 (de) | 1993-03-05 | 2004-11-15 | Wyeth Corp | Plasmid zur herstellung von crm-protein und diphtherie-toxin |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
| PT1117435E (pt) | 1998-09-30 | 2008-02-21 | Us Gov Univ Health Sciences | Holotoxina da cólera mutante como adjuvante |
| GB9906437D0 (en) * | 1999-03-19 | 1999-05-12 | Smithkline Beecham Biolog | Vaccine |
| EP1162999B1 (en) * | 1999-03-19 | 2006-11-29 | Glaxosmithkline Biologicals S.A. | Vaccine against Streptococcus pneumoniae |
| GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| EP1296715B2 (en) * | 2000-06-29 | 2015-12-23 | SmithKline Beecham Biologicals S.A. | Multivalent vaccine composition |
| BR0116756A (pt) | 2000-12-28 | 2005-01-04 | Wyeth Corp | Proteìna protetora recombinante de streptococcus pneumoniae e uso da mesma |
| CA2444133A1 (en) | 2001-04-16 | 2002-10-24 | Wyeth Holdings Corporation | Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
| WO2002098369A2 (en) | 2001-06-07 | 2002-12-12 | Wyeth Holdings Corporation | Mutant forms of cholera holotoxin as an adjuvant |
| ATE451386T1 (de) | 2001-06-07 | 2009-12-15 | Wyeth Corp | Mutantenformen von cholera holotoxin als adjuvans |
| EP1603950A2 (en) | 2003-03-17 | 2005-12-14 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
| EP2425853A1 (en) * | 2005-04-08 | 2012-03-07 | Wyeth LLC | Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition |
| NO346529B1 (no) * | 2005-12-22 | 2022-09-26 | Glaxosmithkline Biologicals Sa | Bruk av et immunogenpreparat for småbarn, omfattende 22F sakkaridkonjugat |
| US8808707B1 (en) * | 2006-05-08 | 2014-08-19 | Wyeth Llc | Pneumococcal dosing regimen |
| SI2167121T1 (sl) * | 2007-06-26 | 2015-12-31 | Glaxosmithkline Biologicals S.A. | Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae |
| EP2424562B1 (en) * | 2009-04-30 | 2015-10-07 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
| TW201136603A (en) * | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
-
2012
- 2012-12-11 KR KR1020120143318A patent/KR20140075201A/ko not_active IP Right Cessation
-
2013
- 2013-12-05 JP JP2015547845A patent/JP2016503016A/ja active Pending
- 2013-12-05 MX MX2015007301A patent/MX366762B/es active IP Right Grant
- 2013-12-05 CN CN201380064973.5A patent/CN104837504A/zh active Pending
- 2013-12-05 DK DK13862871.4T patent/DK2932980T3/da active
- 2013-12-05 BR BR112015013513-7A patent/BR112015013513B1/pt active IP Right Grant
- 2013-12-05 EP EP13862871.4A patent/EP2932980B1/en active Active
- 2013-12-05 WO PCT/KR2013/011195 patent/WO2014092378A1/ko active Application Filing
- 2013-12-05 PL PL13862871T patent/PL2932980T3/pl unknown
- 2013-12-05 RU RU2015121771A patent/RU2613148C2/ru active
- 2013-12-05 PT PT138628714T patent/PT2932980T/pt unknown
- 2013-12-05 ES ES13862871T patent/ES2881541T3/es active Active
- 2013-12-05 US US14/651,046 patent/US20150343076A1/en not_active Abandoned
- 2013-12-05 CA CA2894532A patent/CA2894532C/en active Active
-
2015
- 2015-06-04 PH PH12015501270A patent/PH12015501270A1/en unknown
- 2015-07-06 CO CO15154485A patent/CO7461130A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2932980B1 (en) | 2021-06-30 |
| PL2932980T3 (pl) | 2021-11-08 |
| CN104837504A (zh) | 2015-08-12 |
| RU2015121771A (ru) | 2017-01-19 |
| BR112015013513B1 (pt) | 2023-02-07 |
| WO2014092378A1 (ko) | 2014-06-19 |
| ES2881541T3 (es) | 2021-11-29 |
| AU2013360597A1 (en) | 2015-07-02 |
| PT2932980T (pt) | 2021-07-29 |
| PH12015501270A1 (en) | 2015-08-24 |
| JP2016503016A (ja) | 2016-02-01 |
| KR20140075201A (ko) | 2014-06-19 |
| MX2015007301A (es) | 2016-01-20 |
| RU2613148C2 (ru) | 2017-03-15 |
| US20150343076A1 (en) | 2015-12-03 |
| EP2932980A1 (en) | 2015-10-21 |
| BR112015013513A8 (pt) | 2018-07-31 |
| BR112015013513A2 (pt) | 2017-07-11 |
| CA2894532C (en) | 2020-07-07 |
| EP2932980A4 (en) | 2016-07-06 |
| CA2894532A1 (en) | 2014-06-19 |
| CO7461130A2 (es) | 2015-11-30 |
| MX366762B (es) | 2019-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR23C1020I2 (fr) | Conjugues pyrrolobenzodiazepine-anticorps | |
| DK2932980T3 (da) | Multivalent pneumokok-polysaccharid-proteinkonjugatsammensætning | |
| HK1216894A1 (zh) | 多價結合蛋白組合物 | |
| DK2906251T3 (da) | Pyrrolobenzodiazepin-anti-CD22-antistofkonjugater | |
| BR112015008232A2 (pt) | conjugados pirrolbenzodiazepina-anticorpo | |
| DK3054991T3 (da) | Protein-polymer-lægemiddelkonjugater | |
| BR112014022692A2 (pt) | Molécula de ligação de antígeno multiespecífica | |
| DK2858671T3 (da) | Antistofformulering | |
| DK2890397T3 (da) | Antiprolactinreceptor-antistofformulering | |
| DK3117837T3 (da) | Antistofformuleringer | |
| DK2694038T3 (da) | Farmaceutisk sammensætning | |
| BR112013020540A2 (pt) | métodos para preparação de conjugados | |
| DK3054992T3 (da) | Protein-polymer-lægemiddelkonjugater | |
| BR112013022112A2 (pt) | composição | |
| BR112013022102A2 (pt) | composição | |
| SMT201700110B (it) | Composizione immunogena | |
| DK2729179T3 (da) | Makromolekyler | |
| BR112013020383A2 (pt) | formulações liofilizadas. | |
| BR112014032798A2 (pt) | composição | |
| CO6801637A2 (es) | Formulaciones de anticuerpos | |
| BR112013025845A2 (pt) | formulações com viscosidade reduzida | |
| DK3513806T3 (da) | Immunogen sammensætning | |
| DK2897594T3 (da) | Farmaceutisk sammensætning | |
| DK2917244T3 (da) | Aprotinin-afledte polypeptid-antistofkonjugater | |
| DE112012004678A5 (de) | Faltrad |